GHK-Cu lab monitoring
Which blood work to run before, during and after an injectable GHK-Cu cycle, and what the research can and can't tell you about the results. GHK-Cu is a copper-carrying peptide, not a growth hormone drug, so this panel tracks copper, iron stores, inflammation and the liver. No published study has tested injected GHK-Cu in people. Most human data is from skin products (PMID 42787770), so every test here is a precaution, not a response to a known risk.
When to test
1. Baseline (before you start)
| Marker | Why test it | Standard range |
|---|---|---|
| Serum copper Copper, serum | Your copper reference point. A 1-2 mg dose of GHK-Cu contains roughly 160-320 µg of copper, less than the 900 µg adults need each day. No study has measured serum copper after GHK-Cu. | Adults over 30: men 66-121, women 76-142 µg/dL Source: Labcorp test 001586 |
| Ceruloplasmin Ceruloplasmin | The main copper-carrying protein in blood. It also helps release iron from storage (PMID 23807651), which is why ferritin is on this panel too. | Men 16.0-31.0; women 19.0-39.0 mg/dL Source: Labcorp test 001560 |
| Ferritin Ferritin | Your iron-stores reference point. Copper and iron handling are linked through ceruloplasmin (PMID 23807651). | Depends on age and sex. Labcorp adults 20-40: men 30-400, women 30-150 (the women's upper limit rises with age) ng/mL Source: Labcorp test 004598 |
| CBC Complete blood count | A safety baseline. At high levels, copper can damage red blood cells (PMID 3234858), though that has not been reported at GHK-Cu doses. | WBC 4.0-10 k/mcL; hemoglobin 13-17 g/dL men, 11.5-15.5 g/dL women; platelets 150-400 k/mcL Source: Cleveland Clinic |
| hs-CRP High-sensitivity C-reactive protein | A general inflammation baseline. GHK-Cu lowered inflammatory signals in cells and mice (PMID 35936787, PMID 29986520), but no study has measured CRP in people using it. | Under 1.00 low risk, 1.00-3.00 average, over 3.00 high mg/L Source: Labcorp |
| ESR Erythrocyte sedimentation rate | A second, slower-moving inflammation marker to pair with hs-CRP. | Men 0-15 (under 50), 0-30 (50+); women 0-32 (under 50), 0-40 (50+) mm/hour Source: Labcorp |
| ALT Alanine aminotransferase | The liver is where excess copper does damage; the adult upper limit for copper intake (10 mg a day) is set to protect it (National Academies). A normal GHK-Cu dose is far below that. | 0-45 IU/L Tighter target: 29-33 men, 19-25 women (ACG 2017 healthy upper limit) Source: Cleveland Clinic |
| AST Aspartate aminotransferase | Read alongside ALT. AST is also found in muscle, so hard training in the days before the draw can raise it. | 0-35 IU/L Source: Cleveland Clinic |
2. Mid-cycle (week 4)
tracking only, no expected direction
| Marker | Why test it |
|---|---|
| Serum copper Copper, serum | Confirms copper hasn't climbed above your baseline range. |
| hs-CRP High-sensitivity C-reactive protein | Tracks inflammation against your baseline. |
| ESR Erythrocyte sedimentation rate | Paired with hs-CRP. |
3. Post-cycle (2-4 weeks after your last dose)
| Marker | Why test it |
|---|---|
| Serum copper Copper, serum | Confirms copper stayed in range across the cycle. |
| Ferritin Ferritin | Compare with baseline iron stores. |
| ALT Alanine aminotransferase | Confirms liver enzymes stayed in range. |
| AST Aspartate aminotransferase | Read with ALT; skip hard training for a couple of days before the draw. |
Ranges differ between labs, and copper, ceruloplasmin and ferritin ranges differ by age and sex. Copper, ceruloplasmin, ferritin, hs-CRP and ESR ranges are Labcorp's; ALT, AST and CBC ranges come from Cleveland Clinic. Your own report's printed range is the one to read against.
What to expect
-
Serum copper and ceruloplasmin: expected to stay in range (baseline, week 4, post-cycle)
A 1-2 mg dose of pure GHK-Cu contains roughly 160-320 µg of copper (copper is about 16% of the molecule by weight). That is below the adult daily requirement of 900 µg and far below the 10,000 µg upper limit (National Academies). No study has measured copper or ceruloplasmin after GHK-Cu, so this is arithmetic, not trial data.
If it doesn't: The copper in a normal dose doesn't explain a copper level above range. Stop, retest, and look at other copper sources such as supplements. A much stronger vial than its label says is also possible.
-
ALT and AST: expected to stay in range (baseline to post-cycle)
Copper damages the liver at high intakes (PMID 25199685), but a GHK-Cu dose delivers under 4% of the upper limit. No liver problems have been reported from GHK-Cu.
If it doesn't: A rise above range is not something the research predicts. Stop and retest with a clinician.
-
hs-CRP and ESR: no established change (baseline, week 4, post-cycle)
GHK-Cu's anti-inflammatory effects have only been shown in cells and mice (PMID 35936787, PMID 29986520). If your baseline is normal, expect it to stay normal.
If it doesn't: A flat CRP doesn't mean your GHK-Cu is fake, and a falling one doesn't prove it's real. Inflammation markers move for many reasons. A clear rise is worth a clinician's look.
Your labs can't check your vial
No blood test can confirm what's in your vial, and copper levels won't either: a normal dose carries too little copper to show up. No peer-reviewed study has tested grey-market GHK-Cu for identity or purity. Identity and purity get checked on the product's certificate of analysis, against the testing lab's own record.
What the research doesn't show
- No published study has tested injected GHK-Cu in people, and FDA notes "limited data in humans". The closest is a scalp-injection hair study of a mixed growth-factor formula that included copper tripeptide-1, which can't isolate GHK-Cu's effect (PMID 29482481).
- Most human GHK-Cu data is from skin products, and a 2026 systematic review called for well-designed human trials (PMID 42787770).
- The copper figures assume the powder is pure GHK-Cu and that all its copper becomes available. Neither has been measured.
- Every marker on this panel is a precaution. No study has shown GHK-Cu changes any of them.
Sources
- Najafi N, et al. A systematic review of the mechanisms and therapeutic applications of GHK-Cu (glycyl-L-histidyl-L-lysine-copper). Arch Intern Med Res 2026. PMID 42787770
- Kapoor R, et al. Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth: safety and efficacy evaluation. J Cosmet Laser Ther 2018. PMID 29482481
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci 2018. PMID 29986520
- Zhang Q, et al. Glycyl-L-histidyl-L-lysine-Cu(2+) attenuates cigarette smoke-induced pulmonary emphysema and inflammation. Front Mol Biosci 2022. PMID 35936787
- Vashchenko G, MacGillivray RTA. Multi-copper oxidases and human iron metabolism. Nutrients 2013. PMID 23807651
- Gaetke LM, et al. Copper: toxicological relevance and mechanisms. Arch Toxicol 2014. PMID 25199685
- Fernandes A, et al. Mechanisms of hemolysis induced by copper. Free Radic Res Commun 1988. PMID 3234858
- National Academies: Dietary Reference Intakes, Copper (RDA 900 µg/day; UL 10 mg/day based on liver damage)
- Labcorp test 001586: Copper, serum or plasma (reference range)
- Labcorp test 001560: Ceruloplasmin (reference range)
- Labcorp test 004598: Ferritin (reference ranges by age and sex)
- Cleveland Clinic: Liver function tests (ALT, AST normal ranges)
- Labcorp test 120766: C-reactive protein, high sensitivity (cardiac risk tiers)
- Labcorp test 005215: Sedimentation rate, erythrocyte (reference range)
- Cleveland Clinic: Complete blood count (normal values for adults)
- FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (GHK-Cu, injectable routes)
Educational content, not medical advice. Reference ranges differ by lab, so read your results against the range printed on your own report, and have a clinician review anything out of range.